Multisystem Inflammatory Syndrome in Children: A Comprehensive Review over the Past Five Years This review explores many facets of Multisystem Inflammatory Syndrome in Children (MIS-C) over the previous 5 years. In the time since the COVID 19 pandemic gripped our medical systems, we can now explore the data that has been collected from the previous years. The literature has allowed us to better understand the impact of COVID 19 and the post illness occurrence of a severe systemic inflammatory disease on our youngest patient populations. This paper will outline the pathophysiology of MIS-C, the treatments utilized, short and long-term patient outcomes including epidemiological factors.
VerdoniLMazzaAGervasoniA, et al.An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. Jun 6 2020;395:1771-1778. doi:https://doi.org/10.1016/S0140-6736(20)31103-X
2.
CattaliniMDella PaoleraSZunicaF, et al.Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey. Pediatr Rheumatol Online J. Mar 16 2021;19(1):29. doi:https://doi.org/10.1186/s12969-021-00511-7
3.
ParriNLengeMCantoniB, et al.COVID-19 in 17 Italian Pediatric Emergency Departments. Pediatrics. Dec 2020;146(6). doi:https://doi.org/10.1542/peds.2020-1235
4.
ParriNMagistaAMMarchettiF, et al.Characteristic of COVID-19 infection in pediatric patients: Early findings from two Italian pediatric research networks. Eur J Pediatr. Aug 2020;179(8):1315-1323. doi:https://doi.org/10.1007/s00431-020-03683-8.
5.
DaviesPEvansCKanthimathinathanHK, et al.Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: A multicentre observational study. Lancet Child Adolesc Health. Sep 2020;4(9):669-677. doi:https://doi.org/10.1016/S2352-4642(20)30215-7
6.
MoraledaCSerna-PascualMSoriano-ArandesA, et al.Multi-inflammatory Syndrome in Children Related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Spain. Clin Infect Dis. May 4 2021;72(9):e397-e401. doi:https://doi.org/10.1093/cid/ciaa1042
7.
PoulettyMBoroccoCOuldaliN, et al.Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking kawasaki disease (Kawa-COVID-19): A multicentre cohort. Ann Rheum Dis. Aug 2020;79(8):999-1006. doi: https://doi.org/10.1136/annrheumdis-2020-217960
BerryCSMelbourne-ChambersRHHarrisonAN,et al.Hospitalized children with SARS-CoV-2 infection and MIS-C in Jamaica: A dive into the first 15 months of the novel pandemic. Front Pediatr. 2022;10:904788. doi: https://doi.org/10.3389/fped.2022.904788
10.
DufortEMKoumansEHChowEJ, et al.Multisystem inflammatory syndrome in children in New York state. N Engl J Med. Jul 23 2020;383(4):347-358. doi: https://doi.org/10.1056/NEJMoa2021756
11.
AlsaiedTTremouletAHBurnsJC, et al.Review of Cardiac Involvement in Multisystem Inflammatory Syndrome in Children. Circulation. Jan 5 2021;143(1):78-88. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.049836
12.
SperottoFFriedmanKGSonMBFVanderPluymCJNewburgerJWDionneA. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. Eur J Pediatr. Feb 2021;180(2):307-322. doi: https://doi.org/10.1007/s00431-020-03766-6
13.
HaslakFGunalpAKasapcopurO. A cursed goodbye kiss from severe acute respiratory syndrome-coronavirus-2 to its pediatric hosts: Multisystem inflammatory syndrome in children. Curr Opin Rheumatol. Jan 1 2023;35(1):6-16. doi: https://doi.org/10.1097/BOR.0000000000000910
14.
La TorreFTaddioAContiCCattaliniM. Multi-Inflammatory Syndrome in Children (MIS-C) in 2023: Is It Time to Forget about It?Children (Basel). May 31 2023;10(6). doi: https://doi.org/10.3390/children10060980
15.
SharmaCGanigaraMGaleottiC, et al.Multisystem inflammatory syndrome in children and kawasaki disease: A critical comparison. Nat Rev Rheumatol. Dec 2021;17(12):731-748. doi: https://doi.org/10.1038/s41584-021-00709-9
16.
BoribongBPLaSalleTJBartschYC, et al.Neutrophil profiles of pediatric COVID-19 and multisystem inflammatory syndrome in children. Cell Rep Med. Dec 20 2022;3(12):100848. doi: https://doi.org/10.1016/j.xcrm.2022.100848
17.
CuratolaAChiarettiAFerrettiS,et al.Cytokine Response to SARS-CoV-2 Infection in Children. Viruses. Sep 18 2021;13(9). doi: https://doi.org/10.3390/v13091868
18.
GurlevikSLOzsurekciYSagE, et al.The difference of the inflammatory milieu in MIS-C and severe COVID-19. Pediatr Res. Dec 2022;92(6):1805-1814. doi: https://doi.org/10.1038/s41390-022-02029-4
19.
BarnesBJAdroverJMBaxter-StoltzfusA, et al.Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. Jun 1 2020;217(6). doi: https://doi.org/10.1084/jem.20200652
20.
BorgesLPithon-CuriTCCuriRHatanakaE. COVID-19 and neutrophils: The relationship between hyperinflammation and neutrophil extracellular traps. Mediators Inflamm. Dec 2 2020;2020:8829674. doi: https://doi.org/10.1155/2020/8829674
21.
VerasFPPontelliMCSilvaCM, et al.SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J Exp Med. Dec 7 2020;217(12). doi: https://doi.org/10.1084/jem.20201129
Carmona-RiveraCZhangYDobbsK, et al.Multicenter analysis of neutrophil extracellular trap dysregulation in adult and pediatric COVID-19. JCI Insight. Aug 22 2022;7(16). doi: https://doi.org/10.1172/jci.insight.160332
24.
SeeryVRaidenSCAlgieriSC, et al.Blood neutrophils from children with COVID-19 exhibit both inflammatory and anti-inflammatory markers. EBioMedicine. May 2021;67:103357. doi: https://doi.org/10.1016/j.ebiom.2021.103357
25.
PorrittRAPascholdLRivasMN, et al.HLA class I-associated expansion of TRBV11-2T cells in multisystem inflammatory syndrome in children. J Clin Invest. May 17 2021;131(10). doi: https://doi.org/10.1172/JCI146614
26.
ConsiglioCRCotugnoNSardhF, et al.The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell. Nov 12 2020;183(4):968-981.e7. doi: https://doi.org/10.1016/j.cell.2020.09.016
27.
GruberCNPatelRSTrachtmanR, et al.Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C). Cell. Nov 12 2020;183(4):982-995.e14. doi: https://doi.org/10.1016/j.cell.2020.09.034
28.
WeisbergSPConnorsTJZhuY, et al.Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat Immunol. Jan 2021;22(1):25-31. doi: https://doi.org/10.1038/s41590-020-00826-9
29.
RamaswamyABrodskyNNSumidaTS, et al.Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity. May 11 2021;54(5):1083-1095.e7. doi: https://doi.org/10.1016/j.immuni.2021.04.003
Noval RivasMPorrittRAChengMHBaharIArditiM. Multisystem inflammatory syndrome in children and long COVID: The SARS-CoV-2 viral superantigen hypothesis. Front Immunol. Jul 7 2022;13:941009. doi: https://doi.org/10.3389/fimmu.2022.941009
32.
ChengMHPorrittRARivasMN, et al.A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro. Structure. Sep 2 2021;29(9):951-962.e3. doi: https://doi.org/10.1016/j.str.2021.04.005
33.
WanYShangJSunS, et al.Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J Virol. Feb 14 2020;94(5). doi: https://doi.org/10.1128/JVI.02015-19
34.
DiorioCHenricksonSEVellaLA, et al.Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J Clin Invest. Nov 2 2020;130(11):5967-5975. doi: https://doi.org/10.1172/JCI140970
HalsteadSBKatzelnickLCRussellPK,et al.Ethics of a partially effective dengue vaccine: Lessons from the Philippines. Vaccine. Jul 31 2020;38(35):5572-5576. doi: https://doi.org/10.1016/j.vaccine.2020.06.079
37.
RickeDO. Two different antibody-dependent enhancement (ADE) risks for SARS-CoV-2 antibodies. Front Immunol. Feb 24 2021;12:640093. doi: https://doi.org/10.3389/fimmu.2021.640093
38.
KaneASBoribongBPLoiselleM, et al.Monocyte anisocytosis corresponds with increasing severity of COVID-19 in children. Front Pediatr. Jun 23 2023;11:1177048. doi: https://doi.org/10.3389/fped.2023.1177048
39.
ErdedeOSariEKulcuNUSezer YamanelRG. The role of mean platelet volume in multisystem inflammatory syndrome in children with cardiac manifestations. Pediatr Infect Dis J. Jul 1 2023;42(7):601-607. doi: https://doi.org/10.1097/INF.0000000000003917
40.
SniderJMYouJKWangX, et al.Group IIA secreted phospholipase A2 is associated with the pathobiology leading to COVID-19 mortality. J Clin Invest. Oct 1 2021;131(19). doi: https://doi.org/10.1172/JCI149236
41.
DiorioCShraimRVellaLA, et al.Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction. Nat Commun. Dec 10 2021;12(1):7222. doi: https://doi.org/10.1038/s41467-021-27544-6
DiorioCMcNerneyKOLambertM, et al.Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. Dec 8 2020;4(23):6051-6063. doi: https://doi.org/10.1182/bloodadvances.2020003471
44.
Duarte-NetoANCaldiniEGGomes-GouveaMS, et al.An autopsy study of the spectrum of severe COVID-19 in children: From SARS to different phenotypes of MIS-C. EClinicalMedicine. May 2021;35:100850. doi: https://doi.org/10.1016/j.eclinm.2021.100850
45.
MooreKHMurphyHAGeorgeEM. The glycocalyx: A central regulator of vascular function. Am J Physiol Regul Integr Comp Physiol. Apr 1 2021;320(4):R508-R518. doi: https://doi.org/10.1152/ajpregu.00340.2020
46.
PorrittRABinekAPascholdL, et al.The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children. J Clin Invest. Oct 15 2021;131(20). doi: https://doi.org/10.1172/JCI151520
47.
GelzoMGiannattasioAMaglioneM, et al.Biomarkers of Endothelial Damage in Distinct Phases of Multisystem Inflammatory Syndrome in Children. Metabolites. Jul 24 2022;12(8). doi: https://doi.org/10.3390/metabo12080680
48.
KreslovaMJehlickaPSykorovaA, et al.Circulating Serum Cystatin C as an Independent Risk Biomarker for Vascular Endothelial Dysfunction in Patients with COVID-19-Associated Multisystem Inflammatory Syndrome in Children (MIS-C): A Prospective Observational Study. Biomedicines. Nov 17 2022;10(11). doi: https://doi.org/10.3390/biomedicines10112956
49.
RosenberryRNelsonMD. Reactive hyperemia: A review of methods, mechanisms, and considerations. Am J Physiol Regul Integr Comp Physiol. Mar 1 2020;318(3):R605-R618. doi: https://doi.org/10.1152/ajpregu.00339.2019
50.
BokenkampAHerget-RosenthalSBokenkampR. Cystatin C, kidney function and cardiovascular disease. Pediatr Nephrol. Sep 2006;21(9):1223-1230. doi: https://doi.org/10.1007/s00467-006-0192-5
51.
CiftelMAtasNYilmazO. Investigation of endothelial dysfunction and arterial stiffness in multisystem inflammatory syndrome in children. Eur J Pediatr. Jan 2022;181(1):91-97. doi: https://doi.org/10.1007/s00431-021-04136-6
52.
CiftelMAtasNYilmazO. Correction to: Investigation of endothelial dysfunction and arterial stiffness in multisystem inflammatory syndrome in children. Eur J Pediatr. Nov 15 2023. doi: https://doi.org/10.1007/s00431-023-05310-8
53.
AlaliAO'NeilEAndersM, et al.Vasoplegic shock represents a dominant hemodynamic profile of multisystem inflammatory syndrome following COVID-19 in children and adolescents. Pediatr Crit Care Med. Jun 1 2022;23(6):e295-e299. doi: https://doi.org/10.1097/PCC.0000000000002954
54.
YonkerLMGilboaTOgataAF, et al.Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J Clin Invest. Jul 15 2021;131(14). doi: https://doi.org/10.1172/JCI149633
55.
Mayordomo-ColungaJVivanco-AllendeALopez-AlonsoI,et al.SARS-CoV-2 spike protein in intestinal cells of a patient with coronavirus disease 2019 multisystem inflammatory syndrome. J Pediatr. Apr 2022;243:214-218.e5. doi: https://doi.org/10.1016/j.jpeds.2021.11.058
56.
Jaramillo-EsparzaCMVazquez-FriasR. Risk of pediatric inflammatory multi-system syndrome (PIMS or MIS-C) in pediatric patients with COVID-19 presenting with gastrointestinal symptoms. Front Pediatr. 2022;10:904793. doi: https://doi.org/10.3389/fped.2022.904793
57.
YonkerLMSwankZGilboaT, et al.Zonulin antagonist, larazotide (AT1001), as an adjuvant treatment for multisystem inflammatory syndrome in children: A case series. Crit Care Explor. Feb 2022;10(2):e0641. doi: https://doi.org/10.1097/CCE.0000000000000641
58.
JonePNJohnAOsterME, et al.SARS-CoV-2 infection and associated cardiovascular manifestations and complications in children and young adults: A scientific statement from the American Heart Association. Circulation. May 10 2022;145(19):e1037-e1052. doi: https://doi.org/10.1161/CIR.0000000000001064
59.
CastielloTGeorgiopoulosGFinocchiaroG,et al.COVID-19 and myocarditis: A systematic review and overview of current challenges. Heart Fail Rev. Jan 2022;27(1):251-261. doi: https://doi.org/10.1007/s10741-021-10087-9
60.
ShirbhateEPandeyJPatelVK,et al.Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: A potential approach for therapeutic intervention. Pharmacol Rep. Dec 2021;73(6):1539-1550. doi: https://doi.org/10.1007/s43440-021-00303-6
KellyMSValleCWFernandesNDCummingsBMLahoud-RahmeMChiuJS. Multisystem inflammatory syndrome in children: Cardiac biomarker profiles and echocardiographic findings in the acute and recovery phases. J Am Soc Echocardiogr. Oct 2020;33(10):1288-1290. doi: https://doi.org/10.1016/j.echo.2020.08.008
63.
GhezziMLongoniEMunariA,et al.Lung involvement in children with COVID-19 multisystem inflammatory syndrome. Pediatr Pulmonol. Feb 2023;58(2):615-618. doi: https://doi.org/10.1002/ppul.26224
64.
FerreiraVMSchulz-MengerJHolmvangG, et al.Cardiovascular magnetic resonance in nonischemic myocardial inflammation: Expert recommendations. J Am Coll Cardiol. Dec 18 2018;72(24):3158-3176. doi: https://doi.org/10.1016/j.jacc.2018.09.072
65.
GiryesSMcGonagleD. Immune and non-immune mechanisms that determine vasculitis and coronary artery aneurysm topography in kawasaki disease and MIS-C. Autoimmun Rev. Feb 2023;22(2):103240. doi: https://doi.org/10.1016/j.autrev.2022.103240
66.
DolhnikoffMFerreira FerrantiJde Almeida MonteiroRA, et al.SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome. Lancet Child Adolesc Health. Oct 2020;4(10):790-794. doi: https://doi.org/10.1016/S2352-4642(20)30257-1
67.
de CevinsCLukaMSmithN, et al.A monocyte/dendritic cell molecular signature of SARS-CoV-2-related multisystem inflammatory syndrome in children with severe myocarditis. Med. Sep 10 2021;2(9):1072-1092 e1077. doi: https://doi.org/10.1016/j.medj.2021.08.002
68.
WhittakerEBamfordAKennyJ, et al.Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. Jul 21 2020;324(3):259-269. doi: https://doi.org/10.1001/jama.2020.10369
69.
FeldsteinLRRoseEBHorwitzSM, et al.Multisystem inflammatory syndrome in U.S. Children and adolescents. N Engl J Med. Jul 23 2020;383(4):334-346. doi: https://doi.org/10.1056/NEJMoa2021680
70.
ValverdeISinghYSanchez-de-ToledoJ, et al.Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe. Circulation. Jan 5 2021;143(1):21-32. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.050065
71.
Villacis-NunezDSHashemiSNelsonMC, et al.Giant coronary aneurysms in multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection. JACC Case Rep. Oct 6 2021;3(13):1499-1508. doi: https://doi.org/10.1016/j.jaccas.2021.06.043
72.
HosteLVanPaemelRHaerynckF. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review.Eur J Pediatr. Jul 2021;180(7)248:114-118. doi: https://doi.org/10.1016/j.jpeds.2022.05.028
73.
YasuharaJMasudaKWatanabeK,et al.Longitudinal cardiac outcomes of multisystem inflammatory syndrome in children: A systematic review and meta-analysis. Pediatr Cardiol. Apr 2023;44(4):892-907. doi: https://doi.org/10.1007/s00246-022-03052-2
74.
ThangathuraiJKalashnikovaMTakahashiMShinbaneJS. Coronary artery aneurysm in kawasaki disease: Coronary CT angiography through the Lens of pathophysiology and differential diagnosis. Radiol Cardiothorac Imaging. Oct 2021;3(5):e200550. doi: https://doi.org/10.1148/ryct.2021200550
75.
WinantAJBlumfieldELiszewskiMCKurianJFoustAMLeeEY. Thoracic imaging findings of multisystem inflammatory syndrome in children associated with COVID-19: What radiologists need to know now. Radiol Cardiothorac Imaging. Aug 2020;2(4):e200346. doi: https://doi.org/10.1148/ryct.2020200346
76.
IbrahimHMMohammadSAFoudaE, et al.Clinical characteristics and pulmonary computerized imaging findings of critically ill Egyptian patients with multisystem inflammatory syndrome in children. Glob Pediatr Health. 2022;9:2333794X221085386. doi: https://doi.org/10.1177/2333794X221085386
77.
BikoDMRamirez-SuarezKIBarreraCA,et al.Imaging of children with COVID-19: Experience from a tertiary children's hospital in the United States. Pediatr Radiol. Feb 2021;51(2):239-247. doi: https://doi.org/10.1007/s00247-020-04830-x
78.
Dominguez-RojasJCoronado MunozALuna-DelgadoY, et al.Lung mechanics in pediatric acute respiratory distress syndrome associated to acute COVID-19 and MIS-C: Implications for therapies and outcomes. Andes Pediatr. Jun 2023;94(3):350-360. doi: https://doi.org/10.32641/andespediatr.v94i3.4616
79.
JiangLTangKIrfanOLiXZhangEBhuttaZ. Epidemiology, clinical features, and outcomes of multisystem inflammatory syndrome in children (MIS-C) and adolescents-a live systematic review and meta-analysis. Curr Pediatr Rep. 2022;10(2):19-30. doi: https://doi.org/10.1007/s40124-022-00264-1
80.
PayneABGilaniZGodfred-CatoS, et al.Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. JAMA Netw Open. Jun 1 2021;4(6):e2116420. doi: https://doi.org/10.1001/jamanetworkopen.2021.16420
81.
SonMBFMurrayNFriedmanK, et al.Multisystem inflammatory syndrome in children - initial therapy and outcomes. N Engl J Med. Jul 1 2021;385(1):23-34. doi: https://doi.org/10.1056/NEJMoa2102605
82.
SayedIABhalalaUStromL, et al.Gastrointestinal manifestations in hospitalized children with acute SARS-CoV-2 infection and multisystem inflammatory condition: An analysis of the VIRUS COVID-19 registry. Pediatr Infect Dis J. Sep 1 2022;41(9):751-758. doi: https://doi.org/10.1097/INF.0000000000003589
83.
SahnBEzeOPEdelmanMC,et al.Features of intestinal disease associated with COVID-related multisystem inflammatory syndrome in children. J Pediatr Gastroenterol Nutr. Mar 1 2021;72(3):384-387. doi: https://doi.org/10.1097/MPG.0000000000002953
84.
MillerJBGandhiNClarkeJMcMahanZ. Gastrointestinal involvement in systemic sclerosis: An update. J Clin Rheumatol. Sep 2018;24(6):328-337. doi: https://doi.org/10.1097/RHU.0000000000000626
85.
TangYLiWBaskotaM,et al.Multisystem inflammatory syndrome in children during the coronavirus disease 2019 (COVID-19) pandemic: A systematic review of published case studies. Transl Pediatr. Jan 2021;10(1):121-135. doi: https://doi.org/10.21037/tp-20-188
86.
MillerJCantorAZachariahPAhnDMartinezMMargolisKG. Gastrointestinal symptoms as a Major presentation component of a novel multisystem inflammatory syndrome in children that is related to coronavirus disease 2019: A single center experience of 44 cases. Gastroenterology. Oct 2020;159(4):1571-1574. e1572. doi: https://doi.org/10.1053/j.gastro.2020.05.079
87.
AmorosoADi StasioFRanucciG, et al.Thrombotic features as the primary cause of SARS-CoV-2 related acute abdomen in children. J Pediatr Gastroenterol Nutr. Oct 1 2023;77(4):474-478. doi: https://doi.org/10.1097/MPG.0000000000003893
88.
ChenTHKaoWTTsengYH. Gastrointestinal involvements in children with COVID-related multisystem inflammatory syndrome. Gastroenterology. Apr 2021;160(5):1887-1888. doi: https://doi.org/10.1053/j.gastro.2020.06.084
89.
Vecchio ALGarazzinoSSmarrazzoA, et al.Factors associated with severe gastrointestinal diagnoses in children with SARS-CoV-2 infection or multisystem inflammatory syndrome. JAMA Netw Open. Dec 1 2021;4(12):e2139974. doi: https://doi.org/10.1001/jamanetworkopen.2021.39974
90.
Boybeyi-TurerOOzsurekciYGurlevikSLOygarPDSoyerTTanyelFC. Management of acute abdomen during the active disease course of COVID-19 and multisystem inflammatory syndrome in children. Surg Today. Sep 2022;52(9):1313-1319. doi: https://doi.org/10.1007/s00595-022-02512-9
91.
RimensbergerPCKneyberMCJDeepA, et al.Caring for critically ill children with suspected or proven coronavirus disease 2019 infection: Recommendations by the scientific Sections’ collaborative of the European society of pediatric and neonatal intensive care. Pediatr Crit Care Med. Jan 1 2021;22(1):56-67. doi: https://doi.org/10.1097/PCC.0000000000002599
ChenTH. Neurological involvement associated with COVID-19 infection in children. J Neurol Sci. Nov 15 2020;418:117096. doi: https://doi.org/10.1016/j.jns.2020.117096
94.
KabeerdossJPilaniaRKKarkheleRKumarTSDandaDSinghS. Severe COVID-19, multisystem inflammatory syndrome in children, and kawasaki disease: Immunological mechanisms, clinical manifestations and management. Rheumatol Int. Jan 2021;41(1):19-32. doi: https://doi.org/10.1007/s00296-020-04749-4
95.
MavrogeniSIKolovouGTsirimpisVKafetzisDTsolasGFotisL. The importance of heart and brain imaging in children and adolescents with multisystem inflammatory syndrome in children (MIS-C). Rheumatol Int. Jun 2021;41(6):1037-1044. doi: https://doi.org/10.1007/s00296-021-04845-z
96.
SiracusaLCascioAGiordanoS, et al.Neurological complications in pediatric patients with SARS-CoV-2 infection: A systematic review of the literature. Ital J Pediatr. Jun 2 2021;47(1):123. doi: https://doi.org/10.1186/s13052-021-01066-9
97.
LaRovereKLPoussaintTYYoungCC, et al.Changes in distribution of severe neurologic involvement in US pediatric inpatients with COVID-19 or multisystem inflammatory syndrome in children in 2021 vs 2020. JAMA Neurol. Jan 1 2023;80(1):91-98. doi: https://doi.org/10.1001/jamaneurol.2022.3881
98.
SandovalFJulioKMendezG, et al.Neurologic features associated with SARS-CoV-2 infection in children: A case series report. J Child Neurol. Sep 2021;36(10):853-866. doi: https://doi.org/10.1177/0883073821989164
99.
SaMMirzaLCarterM, et al.Systemic Inflammation Is Associated With Neurologic Involvement in Pediatric Inflammatory Multisystem Syndrome Associated With SARS-CoV-2. Neurol Neuroimmunol Neuroinflamm. Jul 2021;8(4). doi: https://doi.org/10.1212/NXI.0000000000000999
100.
ElmakatyIFerihKKarenO,et al.Clinical Implications of COVID-19 Presence in CSF: Systematic Review of Case Reports. Cells. Oct 13 2022;11(20). doi: https://doi.org/10.3390/cells11203212
101.
LewisAFronteraJPlacantonakisDG,et al.Cerebrospinal fluid in COVID-19: A systematic review of the literature. J Neurol Sci. Feb 15 2021;421:117316. doi: https://doi.org/10.1016/j.jns.2021.117316
102.
O'LoughlinLAlvarez ToledoNBudrieLWaechterRRaynerJ. A systematic review of severe neurological manifestations in pediatric patients with coexisting SARS-CoV-2 infection. Neurol Int. Aug 17 2021;13(3):410-427. doi: https://doi.org/10.3390/neurolint13030041
StarkeyJKobayashiNNumaguchiYMoritaniT. Cytotoxic lesions of the corpus Callosum that show restricted diffusion: Mechanisms, causes, and manifestations. Radiographics. Mar-Apr 2017;37(2):562-576. doi: https://doi.org/10.1148/rg.2017160085
105.
RollinsCKCalderonJWypijD, et al.Neurological and psychological sequelae associated with multisystem inflammatory syndrome in children. JAMA Netw Open. Jul 3 2023;6(7):e2324369. doi: https://doi.org/10.1001/jamanetworkopen.2023.24369
106.
BasalelyAGurusingheSSchneiderJ, et al.Acute kidney injury in pediatric patients hospitalized with acute COVID-19 and multisystem inflammatory syndrome in children associated with COVID-19. Kidney Int. Jul 2021;100(1):138-145. doi: https://doi.org/10.1016/j.kint.2021.02.026
107.
DeepAUpadhyayGdu PreP, et al.Acute kidney injury in pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus-2 pandemic: Experience from PICUs across United Kingdom. Crit Care Med. Dec 2020;48(12):1809-1818. doi: https://doi.org/10.1097/CCM.0000000000004662
108.
SethiSKRanaAAdnaniH, et al.Kidney involvement in multisystem inflammatory syndrome in children: A pediatric nephrologist's perspective. Clin Kidney J. Sep 2021;14(9):2000-2011. doi: https://doi.org/10.1093/ckj/sfab073
109.
LarsenCPBourneTDWilsonJDSaqqaOSharshirMA. Collapsing glomerulopathy in a patient with COVID-19. Kidney Int Rep. Jun 2020;5(6):935-939. doi: https://doi.org/10.1016/j.ekir.2020.04.002
110.
VaduganathanMVardenyOMichelTMcMurrayJJVPfefferMASolomonSD. Renin-Angiotensin-Aldosterone system inhibitors in patients with COVID-19. N Engl J Med. Apr 23 2020;382(17):1653-1659. doi: https://doi.org/10.1056/NEJMsr2005760
111.
SuHYangMWanC, et al.Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. Jul 2020;98(1):219-227. doi: https://doi.org/10.1016/j.kint.2020.04.003
112.
HuangCWangYLiX, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. Feb 15 2020;395(10223):497-506. doi: https://doi.org/10.1016/S0140-6736(20)30183-5
113.
IzzedineHJhaveriKDPerazellaMA. COVID-19 therapeutic options for patients with kidney disease. Kidney Int. Jun 2020;97(6):1297-1298. doi: https://doi.org/10.1016/j.kint.2020.03.015
114.
TripathiAKPilaniaRKBhattGCAtlaniMKumarAMalikS. Acute kidney injury following multisystem inflammatory syndrome associated with SARS-CoV-2 infection in children: A systematic review and meta-analysis. Pediatr Nephrol. Feb 2023;38(2):357-370. doi: https://doi.org/10.1007/s00467-022-05701-3
115.
BouchardJAcharyaACerdaJ, et al.A prospective international multicenter study of AKI in the intensive care unit. Clin J Am Soc Nephrol. Aug 7 2015;10(8):1324-1331. doi: https://doi.org/10.2215/CJN.04360514
116.
RestrepoJMMondragonMVForero-DelgadilloJM, et al.Acute renal failure in children. Multicenter prospective cohort study in medium-complexity intensive care units from the Colombian southeast. PLoS One. 2020;15(8):e0235976. doi: https://doi.org/10.1371/journal.pone.0235976
117.
ShekerdemianLSMahmoodNRWolfeKK, et al.Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr. Sep 1 2020;174(9):868-873. doi: https://doi.org/10.1001/jamapediatrics.2020.1948
118.
KumarRRivkinMJRaffiniL. Thrombotic complications in children with coronavirus disease 2019 and multisystem inflammatory syndrome of childhood. J Thromb Haemost. Sep 2023;21(9):2313-2326. doi: https://doi.org/10.1016/j.jtha.2023.05.020
119.
MartinezFOCombesTWOrsenigoFGordonS. Monocyte activation in systemic COVID-19 infection: Assay and rationale. EBioMedicine. Sep 2020;59:102964. doi: https://doi.org/10.1016/j.ebiom.2020.102964
120.
YuJYuanXChenHChaturvediSBraunsteinEMBrodskyRA. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. Oct 29 2020;136(18):2080-2089. doi: https://doi.org/10.1182/blood.2020008248
121.
NougierCBenoitRSimonM, et al.Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost. Sep 2020;18(9):2215-2219. doi: https://doi.org/10.1111/jth.15016
122.
NicolaiLLeunigABrambsS, et al.Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation. Sep 22 2020;142(12):1176-1189. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.048488
123.
RaffiniLHuangYSWitmerCFeudtnerC. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics. Oct 2009;124(4):1001-1008. doi: https://doi.org/10.1542/peds.2009-0768
124.
CarpenterSLRichardsonTHallM. Increasing rate of pulmonary embolism diagnosed in hospitalized children in the United States from 2001 to 2014. Blood Adv. Jun 26 2018;2(12):1403-1408. doi: https://doi.org/10.1182/bloodadvances.2017013292
125.
FeldsteinLRTenfordeMWFriedmanKG, et al.Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA. Mar 16 2021;325(11):1074-1087. doi: https://doi.org/10.1001/jama.2021.2091
126.
RajputRVSharronMPPavuluriP,et al.Clinical impact of a standardized risk-stratified thromboprophylaxis protocol for multisystem inflammatory syndrome in children. J Pediatr. Nov 2023;262:113624. doi: https://doi.org/10.1016/j.jpeds.2023.113624
127.
WhitworthHSartainSEKumarR, et al.Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood. Jul 15 2021;138(2):190-198. doi: https://doi.org/10.1182/blood.2020010218
128.
TrapaniSRubinoCLasagniD,et al.Thromboembolic complications in children with COVID-19 and MIS-C: A narrative review. Front Pediatr. 2022;10:944743. doi: https://doi.org/10.3389/fped.2022.944743
129.
SchmitzAHWoodKEBurghardtEL,et al.Thromboprophylaxis for children hospitalized with COVID-19 and MIS-C. Res Pract Thromb Haemost. Jul 2022;6(5):e12780. doi: https://doi.org/10.1002/rth2.12780
130.
GoldenbergNASochetAAlbisettiM, et al.Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost. Nov 2020;18(11):3099-3105. doi: https://doi.org/10.1111/jth.15073
131.
SharathkumarAAFaustinoEVSTakemotoCM. How we approach thrombosis risk in children with COVID-19 infection and MIS-C. Pediatr Blood Cancer. Jul 2021;68(7):e29049. doi: https://doi.org/10.1002/pbc.29049
132.
TiwariABalanSRaufA, et al.COVID-19 related multisystem inflammatory syndrome in children (MIS-C): A hospital-based prospective cohort study from kerala. India. BMJ paediatr open. 2021;5(1):e001195. doi: https://doi.org/10.1136/bmjpo-2021-001195
133.
JonatBGeneslawASCaponeCA, et al.Early Treatment of Multisystem Inflammatory Syndrome in Children. Pediatrics. Aug 3 2023. doi: https://doi.org/10.1542/peds.2023-061297
134.
WelzelTAtkinsonASchobiN, et al.Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): An open-label, multicentre, randomised trial. Lancet Child Adolesc Health. Apr 2023;7(4):238-248. doi: https://doi.org/10.1016/S2352-4642(23)00020-2
135.
GambacortaABuonsensoDDe RosaG,et al.Resolution of Giant Coronary Aneurisms in a Child With Refractory Kawasaki Disease Treated With Anakinra. Front Pediatr. 2020;8:195. doi: https://doi.org/10.3389/fped.2020.00195
RosuCAMartensAMSumnerJ, et al.Heterogeneity in the evaluation of suspected MIS-C: A cross-sectional vignette-based survey. BMC Pediatr. Jul 4 2022;22(1):392. doi: https://doi.org/10.1186/s12887-022-03446-4
138.
HarahshehASPortmanMAKhouryM,et al.Management of multisystem inflammatory syndrome in children: Decision-making regarding a new condition in the absence of clinical trial data. Can J Cardiol. Jun 2023;39(6):803-814. doi: https://doi.org/10.1016/j.cjca.2022.11.011
139.
AlgarniASAlamriNMKhayatNZAlabdaliRAAlsubhiRSAlghamdiSH. Clinical practice guidelines in multisystem inflammatory syndrome (MIS-C) related to COVID-19: A critical review and recommendations. World J Pediatr. Deb 2022;18(2):83-90. doi: https://doi.org/10.1007/s12519-021-00499-w
140.
McArdleAJVitoOPatelH, et al.Treatment of multisystem inflammatory syndrome in children. N Engl J Med. Jul 1 2021;385(1):11-22. doi: https://doi.org/10.1056/NEJMoa2102968
141.
OuldaliNToubianaJAntonaD, et al.Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA. Mar 2 2021;325(9):855-864. doi: https://doi.org/10.1001/jama.2021.0694
142.
ShahABAbramsJYGodfred-CatoS, et al.Treatments and severe outcomes for patients diagnosed with MIS-C at four children's hospitals in the United States, March 16, 2020-March 10, 2021. Pediatr Infect Dis J. Nov 1 2023;42(11):990-998. doi: https://doi.org/10.1097/INF.0000000000004065
143.
ColeLDOsborneCMSilveiraLJ, et al.IVIG Compared With IVIG Plus Infliximab in Multisystem Inflammatory Syndrome in Children. Pediatrics. Dec 1 2021;148(6). doi: https://doi.org/10.1542/peds.2021-052702
JonatBGorelikMBoneparthA, et al.Multisystem inflammatory syndrome in children associated with coronavirus disease 2019 in a children's hospital in New York city: Patient characteristics and an institutional protocol for evaluation, management, and follow-up. Pediatr Crit Care Med. Mar 1 2021;22(3):e178-e191. doi: https://doi.org/10.1097/PCC.0000000000002598
146.
DizonBLPRedmondCGotschlichEC, et al.Clinical outcomes and safety of anakinra in the treatment of multisystem inflammatory syndrome in children: A single center observational study. Pediatr Rheumatol Online J. Jul 31 2023;21(1):76. doi: https://doi.org/10.1186/s12969-023-00858-z
147.
BembeaMMLoftisLLThiagarajanRR, et al.Extracorporeal membrane oxygenation characteristics and outcomes in children and adolescents with COVID-19 or multisystem inflammatory syndrome admitted to U.S. ICUs. Pediatr Crit Care Med. May 1 2023;24(5):356-371. doi: https://doi.org/10.1097/PCC.0000000000003212
148.
AbramsJYOsterMEGodfred-CatoSE, et al.Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: A retrospective surveillance study. Lancet Child Adolesc Health. May 2021;5(5):323-331. doi: https://doi.org/10.1016/S2352-4642(21)00050-X
149.
MerckxJCookeSEl TalT, et al.Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: A multicentre cohort study. CMAJ. Apr 11 2022;194(14):E513-E523. doi: https://doi.org/10.1503/cmaj.210873
150.
NaberCEFernandesNDLahoud-RahmeM, et al.Operational innovation in the provision of pediatric extracorporeal membrane oxygenation for multisystem inflammatory syndrome in children. Health Secur. 2022;20(1):50-57. doi: https://doi.org/10.1089/hs.2021.0119
151.
EmeksizSOzcanSPerkO, et al.Therapeutic plasma exchange: A potential management strategy for critically ill MIS-C patients in the pediatric intensive care unit. Transfus Apher Sci. Jun 2021;60(3):103119. doi: https://doi.org/10.1016/j.transci.2021.103119
152.
HeadJRCollenderPALeonTM, et al.COVID-19 Vaccination and incidence of pediatric SARS-CoV-2 infection and hospitalization. JAMA Netw Open. Apr 1 2024;7(4):e247822. doi: https://doi.org/10.1001/jamanetworkopen.2024.7822
153.
YousafARMillerADLindseyK,et al.Multisystem inflammatory syndrome in children among persons who completed a two-dose COVID-19 vaccine primary series compared with those reporting No COVID-19 vaccination, US national MIS-C surveillance. Pediatr Infect Dis J. Dec 1 2023;42(12):e476-e478. doi: https://doi.org/10.1097/INF.0000000000004103
154.
ZhangYFXiaCYYangQ,et al.The protective effects of pediatric vaccination on multisystem inflammatory syndrome in children stratified by vaccine status, types and virus variants. Int Immunopharmacol. Dec 2023;125:111105. doi: https://doi.org/10.1016/j.intimp.2023.111105
Le MarchandCSingsonJRCClarkA, et al.Multisystem inflammatory syndrome in children (MIS-C) cases by vaccination status in California. Vaccine. Jan 1 2025;43(Pt 1):126499. doi: https://doi.org/10.1016/j.vaccine.2024.126499
157.
WalterEBTalaatKRSabharwalC, et al.Evaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age. N Engl J Med. Jan 6 2022;386(1):35-46. doi: https://doi.org/10.1056/NEJMoa2116298
158.
FowlkesALYoonSKLutrickK, et al.Effectiveness of 2-dose BNT162b2 (pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5-11 years and adolescents aged 12-15 years - PROTECT cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep. Mar 18 2022;71(11):422-428. doi: https://doi.org/10.15585/mmwr.mm7111e1
159.
KleinNPStockwellMSDemarcoM, et al.Effectiveness of COVID-19 pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years - VISION network, 10 states, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. Mar 4 2022;71(9):352-358.
160.
WatanabeAKaniRIwagamiMTakagiHYasuharaJKunoT. Assessment of efficacy and safety of mRNA COVID-19 vaccines in children aged 5 to 11 years: A systematic review and meta-analysis. JAMA Pediatr. Apr 1 2023;177(4):384-394. doi: https://doi.org/10.1001/jamapediatrics.2022.6243
161.
YousafARLindseyKNWuMJ, et al.Notes from the field: Surveillance for multisystem inflammatory syndrome in children - United States, 2023. MMWR Morb Mortal Wkly Rep. Mar 14 2024;73(10):225-228. doi: https://doi.org/10.15585/mmwr.mm7310a2
162.
YousafARCorteseMMTaylorAW, et al.Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: A surveillance investigation. Lancet Child Adolesc Health. May 2022;6(5):303-312. doi: https://doi.org/10.1016/S2352-4642(22)00028-1
163.
JainSSAndersonSASteeleJM, et al.Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: Longitudinal results from the myocarditis after COVID vaccination (MACiV) multicenter study. EClinicalMedicine. Oct 2024;76:102809. doi: https://doi.org/10.1016/j.eclinm.2024.102809
164.
PatoneMMeiXWHandunnetthiL, et al.Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex. Circulation. Sep 6 2022;146:743-754. doi: https://doi.org/10.1161/CIRCULATIONAHA.122.059970
165.
YuCKTsaoSNgCW, et al.Cardiovascular assessment up to one year after COVID-19 vaccine-associated myocarditis. Circulation. Aug 2023;148(5):436-439. doi: https://doi.org/10.1161/CIRCULATIONAHA.123.064772
166.
SoePVanderkooiOGSadaranganiM, et al.mRNA COVID-19 vaccine safety among children and adolescents: A Canadian national vaccine safety network cohort study. Lancet Reg Health Am. Dec 2024;40:100949. doi: https://doi.org/10.1016/j.lana.2024.100949
167.
SmithJSchraderSMorganH, et al.Clinical phenotype of COVID-19 vaccine-associated myocarditis in Victoria, 2021-22: a cross-sectional study. Med J Aust. Dec 10 2024. doi: https://doi.org/10.5694/mja2.52557
168.
McCayNBeirneNBeretonEHealyMFranklinO. COVID-19 and PIMS-TS-related admissions to paediatric intensive care in the republic of Ireland January 2020 and July 2022 and analysis of cardiovascular manifestations of their disease. Cardiol Young. Nov 28 2024:1-6. doi: https://doi.org/10.1017/S1047951124025733
169.
Le VuSBertrandMSemenzatoL, et al.Influence of mRNA COVID-19 vaccine dosing interval on the risk of myocarditis. Nat Commun. Sep 5 2024;15(1):7745. doi: https://doi.org/10.1038/s41467-024-52038-6
170.
HviidANieminenTAPihlstromN, et al.Booster vaccination with SARS-CoV-2 mRNA vaccines and myocarditis in adolescents and young adults: A nordic cohort study. Eur Heart J. Apr 14 2024;45(15):1327-1335. doi: https://doi.org/10.1093/eurheartj/ehae056
171.
LeeNKimKHParkJH, et al.COVID-19 Vaccination-Related pericarditis: A Korean nationwide study. Mayo Clin Proc. Oct 2024;99(10):1577-1588. doi: https://doi.org/10.1016/j.mayocp.2024.03.026
172.
ThamMYChanCLTohD, et al.An updated analysis on myocarditis and pericarditis cases reported following mRNA SARS-CoV-2 vaccination in Singapore. Singapore Med J. Feb 16 2024. doi: https://doi.org/10.4103/singaporemedj.SMJ-2023-089
173.
NvBMcCollumSFahertyESteeleJMKarnikR. Longitudinal assessment of left ventricular function in patients with myopericarditis after mRNA COVID-19 vaccination. Pediatr Cardiol. Oct 2024;45(7):1524-1532. doi: https://doi.org/10.1007/s00246-023-03200-2
174.
AmodioDPascucciGRCotugnoN, et al.Similarities and differences between myocarditis following COVID-19 mRNA vaccine and multiple inflammatory syndrome with cardiac involvement in children. Clin Immunol. Oct 2023;255:109751. doi: https://doi.org/10.1016/j.clim.2023.109751
175.
TruongDTHartyBJBaintonJ, et al.Design and rationale of the COVID vaccine-associated myocarditis/pericarditis (CAMP) study. Am Heart J. Nov 26 2024;281:32-42. doi: https://doi.org/10.1016/j.ahj.2024.11.008
176.
MunroAPSJonesCEFaustSN. Vaccination against COVID-19 - risks and benefits in children. Eur J Pediatr. Mar 2024;183(3):1107-1112. doi: https://doi.org/10.1007/s00431-023-05380-8
177.
YousafARKunkelAAbramsJY, et al.COVID-19 Vaccine reactogenicity and vaccine attitudes among children and parents/guardians after multisystem inflammatory syndrome in children or COVID-19 hospitalization: September 2021-may 2022. Pediatr Infect Dis J. Mar 1 2023;42(3):252-259. doi: https://doi.org/10.1097/INF.0000000000003803
178.
MullinsEHudakMLBanerjeeJ, et al.Pregnancy and neonatal outcomes of COVID-19: Coreporting of common outcomes from PAN-COVID and AAP-SONPM registries. Ultrasound Obstet Gynecol. Apr 2021;57(4):573-581. doi: https://doi.org/10.1002/uog.23619
179.
RaschettiRVivantiAJVauloup-FellousCLoiBBenachiADe LucaD. Synthesis and systematic review of reported neonatal SARS-CoV-2 infections. Nat Commun.Oct 15 2020;11(1):5164. doi: https://doi.org/10.1038/s41467-020-18982-9
180.
HoffmannMKleine-WeberHSchroederS, et al.SARS-CoV-2 cell entry Depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. Apr 16 2020;181(2):271-280 e278. doi: https://doi.org/10.1016/j.cell.2020.02.052
181.
MascarenhasDGoyalMHaribalakrishnaANanavatiRIshPKunalS. Multisystem inflammatory syndrome in neonates (MIS-N): A systematic review. Eur J Pediatr. May 2023;182(5):2283-2298. doi: https://doi.org/10.1007/s00431-023-04906-4
182.
PawarRGavadeVPatilN, et al.Neonatal Multisystem Inflammatory Syndrome (MIS-N) Associated with Prenatal Maternal SARS-CoV-2: A Case Series. Children (Basel). Jul 2 2021;8(7). doi: https://doi.org/10.3390/children8070572
183.
HechtJLQuadeBDeshpandeV, et al.SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: A series of 19 placentas from COVID-19-positive mothers. Mod Pathol. Nov 2020;33(11):2092-2103. doi: https://doi.org/10.1038/s41379-020-0639-4
184.
MolloyEJNakraNGaleCDimitriadesVRLakshminrusimhaS. Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: Optimizing definition and management. Pediatr Res. May 2023;93(6):1499-1508. doi: https://doi.org/10.1038/s41390-022-02263-w
185.
NakraNABlumbergDAHerrera-GuerraALakshminrusimhaS. Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. Children (Basel). Jul 1 2020;7(7). doi: https://doi.org/10.3390/children7070069
186.
RoySJhaVNRanjanB. A case series of coagulopathy in preterm or growth-restricted term neonates born to mothers with antenatal SARS-CoV-2 infection: Neonatal post-COVID-19 coagulopathy?J Family Med Prim Care. Nov 2022;11(11):7483-7490. doi: https://doi.org/10.4103/jfmpc.jfmpc_1284_22
187.
MartinsAPolicarpoSSilva-PintoA,et al.SARS-CoV-2-related multisystem inflammatory syndrome in adults. Eur J Case Rep Intern Med. 2021;8(11):003025. doi: https://doi.org/10.12890/2021_003025
188.
AbramsJYBelayEDGodfred-CatoS, et al.Trends in treatments for multisystem inflammatory syndrome in children (MIS-C), United States, February 2020 - July 2021. Clin Infect Dis. Sep 30 2022;75(7):1201-1209. doi: https://doi.org/10.1093/cid/ciac072
189.
ChenCJKaoHYHuangCHLiCJHungCHYongSB. New insight into the intravenous immunoglobulin treatment in multisystem inflammatory syndrome in children and adults. Ital J Pediatr. Jan 25 2024;50(1):18. doi: https://doi.org/10.1186/s13052-024-01585-1
190.
KunalSIshPSakthivelPMalhotraNGuptaK. The emerging threat of multisystem inflammatory syndrome in adults (MIS-A) in COVID-19: A systematic review. Heart Lung. Jul-Aug 2022;54:7-18. doi: https://doi.org/10.1016/j.hrtlng.2022.03.007
191.
PatelPDeCuirJAbramsJCampbellAPGodfred-CatoSBelayED. Clinical characteristics of multisystem inflammatory syndrome in adults: A systematic review. JAMA Netw Open. Sep 1 2021;4(9):e2126456. doi: https://doi.org/10.1001/jamanetworkopen.2021.26456
192.
SnooksKScanlonMCRemyKE, et al.Characteristics and outcomes of critically ill children with multisystem inflammatory syndrome. Pediatr Crit Care Med. Nov 1 2022;23(11):e530-e535. doi: https://doi.org/10.1097/PCC.0000000000003054
193.
ShingletonJBurtonLWilliamsHE, et al.Risk of paediatric multisystem inflammatory syndrome (PIMS-TS) during the SARS-CoV-2 alpha and delta variant waves: National observational and modelling study, 2020-21, England. Front Pediatr. 2022;10:1034280. doi: https://doi.org/10.3389/fped.2022.1034280
194.
MartinBDeWittPERussellS, et al.Characteristics, outcomes, and severity risk factors associated with SARS-CoV-2 infection among children in the US national COVID cohort collaborative. JAMA Netw Open. Feb 1 2022;5(2):e2143151. doi: https://doi.org/10.1001/jamanetworkopen.2021.43151
195.
MillerADYousafARBornsteinE, et al.Multisystem inflammatory syndrome in children during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta and omicron variant circulation-United States, July 2021-January 2022. Clin Infect Dis. Oct 3 2022;75(Suppl 2):S303-S307. doi: https://doi.org/10.1093/cid/ciac471
196.
MillerADZambranoLDYousafAR, et al.Correction to: Multisystem inflammatory syndrome in children-United States, February 2020-July 2021. Clin Infect Dis. Aug 24 2022;75(1):186. doi: https://doi.org/10.1093/cid/ciac253
197.
BowenAMillerADZambranoLD,et al.Demographic and clinical factors associated with death among persons <21 years old with multisystem inflammatory syndrome in children-United States, February 2020-march 2021. Open Forum Infect Dis. Aug 2021;8(8):ofab388. doi: https://doi.org/10.1093/ofid/ofab388
198.
WhittakerRGreve-IsdahlMBoasHSurenPBuanesEAVenetiL. COVID-19 Hospitalization Among Children <18 Years by Variant Wave in Norway. Pediatrics. Sep 1 2022;150(3). doi: https://doi.org/10.1542/peds.2022-057564
199.
LopezLBurgnerDGloverC, et al.Lower risk of multi-system inflammatory syndrome in children (MIS-C) with the omicron variant. Lancet Reg Health West Pac. Oct 2022;27:100604. doi: https://doi.org/10.1016/j.lanwpc.2022.100604
200.
LopezLBurgnerDGloverC, et al.Corrigendum to "Lower risk of multi-system Inflammatory Syndrome in Children (MIS-C) with the Omicron variant" [The Lancet Regional Health - Western Pacific 27 (2022) 100604]. Lancet Reg Health West Pac. Jun 2023;35:100808. doi: https://doi.org/10.1016/j.lanwpc.2023.100808
201.
SperottoFGutierrez-SacristanAMakwanaS, et al.Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: A multinational study from the 4CE consortium. EClinicalMedicine. Oct 2023;64:102212. doi: https://doi.org/10.1016/j.eclinm.2023.102212
202.
RaoSJingNLiuX, et al.Spectrum of severity of multisystem inflammatory syndrome in children: An EHR-based cohort study from the RECOVER program. Sci Rep. Nov 28 2023;13(1):21005. doi: https://doi.org/10.1038/s41598-023-47655-y
203.
DinsmoreNMcRaeJEQuinnHE, et al.Paediatric Active Enhanced Disease Surveillance (PAEDS) 2019: Prospective hospital-based surveillance for serious paediatric conditions. Commun Dis Intell (2018). Sep 30 2021;45. doi: https://doi.org/10.33321/cdi.2021.45.53
204.
CohenJMCarterMJCheungCRLadhaniS. Evelina paediatric inflammatory multisystem syndrome temporally related to S-C-SG. Lower risk of multisystem inflammatory syndrome in children with the Delta and omicron variants of severe acute respiratory syndrome coronavirus 2. Clin Infect Dis. Feb 8 2023;76(3):e518-e521. doi: https://doi.org/10.1093/cid/ciac553
205.
HolmMEspenhainLGlenthojJ,et al.Risk and phenotype of multisystem inflammatory syndrome in vaccinated and unvaccinated danish children before and during the omicron wave. JAMA Pediatr. Aug 1 2022;176(8):821-823. doi: https://doi.org/10.1001/jamapediatrics.2022.2206
206.
LevyNKoppelJHKaplanO,et al.Severity and incidence of multisystem inflammatory syndrome in children during 3 SARS-CoV-2 pandemic waves in Israel. JAMA. Jun 28 2022;327(24):2452-2454. doi: https://doi.org/10.1001/jama.2022.8025
207.
MillerADZambranoLDYousafAR, et al.Multisystem inflammatory syndrome in children-United States, February 2020-July 2021. Clin Infect Dis. Aug 24 2022;75(1):e1165-e1175. doi: https://doi.org/10.1093/cid/ciab1007
208.
GoyalMKSimpsonJNBoyleMD,et al.Racial and/or Ethnic and Socioeconomic Disparities of SARS-CoV-2 Infection Among Children. Pediatrics. Oct 2020;146(4). doi: https://doi.org/10.1542/peds.2020-009951
209.
JavalkarKRobsonVKGaffneyL, et al.Socioeconomic and Racial and/or Ethnic Disparities in Multisystem Inflammatory Syndrome. Pediatrics. May 2021;147(5). doi: https://doi.org/10.1542/peds.2020-039933
210.
SikGInamlikAAkcayN, et al.Mortality risk factors among critically ill children with MIS-C in PICUs: A multicenter study. Pediatr Res. Aug 2023;94(2):730-737. doi: https://doi.org/10.1038/s41390-023-02518-0
211.
NachegaJBSam-AguduNAMachekanoRN, et al.Assessment of clinical outcomes among children and adolescents hospitalized with COVID-19 in 6 sub-saharan African countries. JAMA Pediatr. Mar 1 2022;176(3):e216436. doi: https://doi.org/10.1001/jamapediatrics.2021.6436
212.
Lima-SettaFMagalhaes-BarbosaMCRodrigues-SantosG, et al.Multisystem inflammatory syndrome in children (MIS-C) during SARS-CoV-2 pandemic in Brazil: A multicenter, prospective cohort study. J Pediatr (Rio J). May-Jun 2021;97(3):354-361. doi: https://doi.org/10.1016/j.jped.2020.10.008
213.
AlmeidaFJJarovskyDAlmeida FariasCG, et al.High Fatality Rates in Pediatric Multisystem Inflammatory Syndrome: A Multicenter Experience From the Epicenter of Brazil's Coronavirus Pandemic. Pediatr Infect Dis J. Nov 22 2023. doi: https://doi.org/10.1097/INF.0000000000004164
214.
IrfanOMuttalibFTangKJiangLLassiZSBhuttaZ. Clinical characteristics, treatment and outcomes of paediatric COVID-19: A systematic review and meta-analysis. Arch Dis Child. Feb 16 2021;106(5):440-448. doi: https://doi.org/10.1136/archdischild-2020-321385
215.
CaponeCAMisraNGanigaraM, et al.Six Month Follow-up of Patients With Multi-System Inflammatory Syndrome in Children. Pediatrics. Oct 2021;148(4). doi: https://doi.org/10.1542/peds.2021-050973
216.
KahnRBergSBerntsonL, et al.Population-based study of multisystem inflammatory syndrome associated with COVID-19 found that 36% of children had persistent symptoms. Acta Paediatr. Feb 2022;111(2):354-362. doi: https://doi.org/10.1111/apa.16191
217.
MadduxABBerbertLYoungCC, et al.Health Impairments in Children and Adolescents After Hospitalization for Acute COVID-19 or MIS-C. Pediatrics. Sep 1 2022;150(3). doi: https://doi.org/10.1542/peds.2022-057798
218.
MadduxABYoungCCKucukakS, et al.Risk factors for health impairments in children after hospitalization for acute COVID-19 or MIS-C. Front Pediatr. 2023;11:1260372. doi: https://doi.org/10.3389/fped.2023.1260372
219.
Ashkenazi-HoffnungLShmueliEEhrlichS,et al.Long COVID in children: Observations from a designated pediatric clinic. Pediatr Infect Dis J. Dec 1 2021;40(12):e509-e511. doi: https://doi.org/10.1097/INF.0000000000003285
220.
BuonsensoDMunblitDDe RoseC,et al.Preliminary evidence on long COVID in children. Acta Paediatr. Jul 2021;110(7):2208-2211. doi: https://doi.org/10.1111/apa.15870
LudvigssonJF. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. Mar 2021;110(3):914-921. doi: https://doi.org/10.1111/apa.15673
223.
SayDCrawfordNMcNabSWurzelDSteerATosifS. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. Lancet Child Adolesc Health. Jun 2021;5(6):e22-e23. doi: https://doi.org/10.1016/S2352-4642(21)00124-3
